Cancer Genetics (NASDAQ:CGIX) announced its quarterly earnings data on Tuesday. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02, MarketWatch Earnings reports. Cancer Genetics had a negative return on equity of 121.10% and a negative net margin of 87.08%.
Shares of NASDAQ CGIX opened at $0.26 on Wednesday. The firm has a market capitalization of $7.15 million, a PE ratio of -0.33 and a beta of 1.17. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.46 and a current ratio of 0.46. Cancer Genetics has a 12-month low of $0.20 and a 12-month high of $1.46.
Separately, ValuEngine upgraded Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.
In other Cancer Genetics news, CEO John A. Roberts purchased 185,436 shares of the business’s stock in a transaction on Thursday, January 31st. The shares were bought at an average cost of $0.23 per share, for a total transaction of $42,650.28. Following the completion of the purchase, the chief executive officer now directly owns 297,636 shares in the company, valued at $68,456.28. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Glenn Miles purchased 150,000 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was acquired at an average price of $0.23 per share, for a total transaction of $34,500.00. Following the completion of the purchase, the chief financial officer now owns 150,000 shares of the company’s stock, valued at $34,500. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 1,335,436 shares of company stock worth $307,150. Insiders own 21.30% of the company’s stock.
An institutional investor recently raised its position in Cancer Genetics stock. Geode Capital Management LLC raised its holdings in Cancer Genetics Inc (NASDAQ:CGIX) by 106.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,803 shares of the medical research company’s stock after buying an additional 114,448 shares during the period. Geode Capital Management LLC owned about 0.80% of Cancer Genetics worth $53,000 as of its most recent SEC filing. 9.00% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Cancer Genetics (CGIX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thestockobserver.com/2019/04/17/cancer-genetics-cgix-releases-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.
Cancer Genetics Company Profile
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Recommended Story: Leveraged Buyout (LBO)
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.